Trial Profile
An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Dapagliflozin (Primary)
- Indications Cardiovascular disorders; COVID 2019 infections; Respiratory insufficiency
- Focus Therapeutic Use
- Acronyms DARE-19
- 29 Aug 2023 Meta-analysis results from DARE-19, RECOVERY and ACTIV-4A trials presented in Escardio media release.
- 29 Aug 2023 According to Escardio media release, meta-analysis from DARE-19, RECOVERY and ACTIV-4A trials ( N=6,096) presented in a Hot Line session today at ESC Congress 2023.
- 13 Sep 2021 Status changed from active, no longer recruiting to completed.